CompletedNCT01614899
A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia
Researchers compared SM-13496 40mg, SM-13496 80mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 18–74Multiple countries
Understand this study
What did researchers investigate?
Researchers compared SM-13496 40mg, SM-13496 80mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 74 years. Other eligibility criteria applied.
- Listed locations
- Tokyo, Etc and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2, 2012
- Recruitment status
- Completed
- Enrollment listed in the registry
- 457
- Sponsor
- Sumitomo Pharma Co., Ltd.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan, Malaysia, South Korea, ...
- Age range
- From 18 Years to 74 Years
- Official registry ID
- NCT01614899
- Official title
Show the full official title
Randomized, Double-blind, Parallel- Group, Placebo-controlled, Confirmatory Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia <Phase 3>
Get this study by email
Recruitment & locations
CompletedTokyo, Etc, Japan · Kuala Lumpur, Etc, Malaysia · Seoul, Etc, South Korea
1 more locations
- Taipei, Etc, Taiwan
Questions about this study
What did researchers investigate?
Researchers compared SM-13496 40mg, SM-13496 80mg and placebo to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Sumitomo Pharma Co., Ltd., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including SM-13496 40mg, SM-13496 80mg and Placebo.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: 18 years to 74 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
A 6-WEEK RANDOMIZED, PARALLEL, DOUBLE-BLIND, PLACEBO-CONTROLLED, FIXED-DOSE, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENT SUBJECTS WITH SCHIZOPHRENIA
A 6-week Study to Evaluate the Efficacy and Safety of Lurasidone HCL in Acutely Psychotic Patients With Schizophrenia